Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The wound healing, chronic fibrosis, and cancer progression triad.

ABSTRACT: For decades tumors have been recognized as "wounds that do not heal." Besides the commonalities that tumors and wounded tissues share, the process of wound healing also portrays similar characteristics with chronic fibrosis. In this review, we suggest a tight interrelationship, which is governed as a concurrence of cellular and microenvironmental reactivity among wound healing, chronic fibrosis, and cancer development/progression (i.e., the WHFC triad). It is clear that the same cell types, as well as soluble and matrix elements that drive wound healing (including regeneration) via distinct signaling pathways, also fuel chronic fibrosis and tumor progression. Hence, here we review the relationship between fibrosis and cancer through the lens of wound healing.

SUBMITTER: Rybinski B

PROVIDER: S-EPMC4035661 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

The wound healing, chronic fibrosis, and cancer progression triad.

Rybinski Brad B Franco-Barraza Janusz J Cukierman Edna E

Physiological genomics 20140211 7

For decades tumors have been recognized as "wounds that do not heal." Besides the commonalities that tumors and wounded tissues share, the process of wound healing also portrays similar characteristics with chronic fibrosis. In this review, we suggest a tight interrelationship, which is governed as a concurrence of cellular and microenvironmental reactivity among wound healing, chronic fibrosis, and cancer development/progression (i.e., the WHFC triad). It is clear that the same cell types, as w ...[more]

PMID: 24520152

Similar Datasets

Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing.

Project description:Accumulating evidence indicates that there is extensive crosstalk between integrins and TGF-beta signalling. TGF-beta affects integrin-mediated cell adhesion and migration by regulating the expression of integrins, their ligands and integrin-associated proteins. Conversely, several integrins directly control TGF-beta activation. In addition, a number of integrins can interfere with both Smad-dependent and Smad-independent TGF-beta signalling in different ways, including the regulation of the expression of TGF-beta signalling pathway components, the physical association of integrins with TGF-beta receptors and the modulation of downstream effectors. Reciprocal TGF-beta-integrin signalling is implicated in normal physiology, as well as in a variety of pathological processes including systemic sclerosis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and cancer; thus, integrins could provide attractive therapeutic targets to interfere with TGF-beta signalling in these processes.

| S-EPMC2828749 | biostudies-other

Examination of matricellular fibrosis and wound healing in a model of pancreatic cancer progression

Project description:Pancreatic ductal adenocarcinoma (PDAC) has the highest amount of stroma when compared to other solid tumors. It is now well known that the stroma plays an important role in supporting pancreatic cancer development and progression and this knowledge has led to the development of potential anti-stromal therapies, some of which have shown synergistic effect in combination with gemcitabine. Despite the acknowledgement of its importance, a granular view of how stromal composition and cross-linking change during the course of PDAC progression remains unfounded. Generally, the fibrosis that occurs in solid tumors appears to be driven primarily by increases in the abundance of fibrillar collagen, whose insolubility is determined by the formation of covalent intermolecular cross-links. Here we have used semi-quantitative proteomics and cross-linked amino acid analysis to characterize the composition and crosslinking status of normal pancreatic and PDAC stroma. In order to mimic the desmoplastic stroma observed in human disease, we utilized the genetically engineered KTC mouse model of PDAC (KrasLSL-G12D/+Tgfbr2flox/+Ptf1a-Cre). We found that highly fibrotic PDACs alter the solubility of their collagen-rich stroma through changes in the abundance of collagen cross-links and supports development of matricellular fibrosis associated with a wound healing response.

| MSV000081553 | MassIVE

Nanobiotechnology: Applications in Chronic Wound Healing.

Project description:Wounds occur when skin integrity is broken and the skin is damaged. With progressive changes in the disease spectrum, the acute wounds caused by mechanical trauma have been become less common, while chronic wounds triggered with aging, diabetes and infection have become more frequent. Chronic wounds now affect more than 6 million people in the United States, amounting to 10 billion dollars in annual expenditure. However, the treatment of chronic wounds is associated with numerous challenges. Traditional remedies for chronic wounds include skin grafting, flap transplantation, negative-pressure wound therapy, and gauze dressing, all of which can cause tissue damage or activity limitations. Nanobiotechnology - which comprises a diverse array of technologies derived from engineering, chemistry, and biology - is now being applied in biomedical practice. Here, we review the design, application, and clinical trials for nanotechnology-based therapies for chronic wound healing, highlighting the clinical potential of nanobiotechnology in such treatments. By summarizing previous nanobiotechnology studies, we lay the foundation for future wound care via a nanotech-based multifunctional smart system.

| S-EPMC9309282 | biostudies-literature

Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.

Project description:Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a devastating skin blistering disease caused by mutations in the gene encoding type VII collagen (C7), leading to epidermal fragility, trauma-induced blistering, and long term, hard-to-heal wounds. Fibrosis develops rapidly in RDEB skin and contributes to both chronic wounds, which emerge after cycles of repetitive wound and scar formation, and squamous cell carcinoma-the single biggest cause of death in this patient group. The molecular pathways disrupted in a broad spectrum of fibrotic disease are also disrupted in RDEB, and squamous cell carcinomas arising in RDEB are thus far molecularly indistinct from other sub-types of aggressive squamous cell carcinoma (SCC). Collectively these data demonstrate RDEB is a model for understanding the molecular basis of both fibrosis and rapidly developing aggressive cancer. A number of studies have shown that RDEB pathogenesis is driven by a radical change in extracellular matrix (ECM) composition and increased transforming growth factor-beta (TGFβ) signaling that is a direct result of C7 loss-of-function in dermal fibroblasts. However, the exact mechanism of how C7 loss results in extensive fibrosis is unclear, particularly how TGFβ signaling is activated and then sustained through complex networks of cell-cell interaction not limited to the traditional fibrotic protagonist, the dermal fibroblast. Continued study of this rare disease will likely yield paradigms relevant to more common pathologies.

| S-EPMC8151646 | biostudies-literature

Predicting Chronic Wound Healing Time Using Machine Learning

Project description:Objective: Chronic wounds have risen to epidemic proportions in the United States and can have an emotional, physical, and financial toll on patients. By leveraging data within the electronic health record (EHR), machine learning models offer the opportunity to facilitate earlier identification of wounds at risk of not healing or healing after an abnormally long time, which may improve treatment decisions and patient outcomes. Machine learning models in this study were built to predict chronic wound healing time. Approach: Machine learning models were developed using EHR data to predict patients at risk of having wounds not heal within 4, 8, and 12 weeks from the start of treatment. The models were trained on three data sets of 1,220,576 wounds, including 187 covariates describing patient demographics, comorbidities, and wound characteristics. The area under the receiver operating characteristic curve (AUC) was used to assess the accuracy of the models. Shapley Additive Explanations (SHAP) were used to analyze variable importance in predictions and enhance clinical interpretations. Results: The 4-, 8-, and 12-week gradient-boosted decision tree models achieved AUC's of 0.854, 0.855, and 0.853, respectively. Days in treatment, wound depth and location, and wound area were the most influential predictors of wounds at risk of not healing. Innovation: Machine learning models can accurately predict chronic wound healing time using EHR data. SHAP values can give insight into how patient-specific variables influenced predictions. Conclusion: Accurate models identifying patients with chronic wounds at risk of non or slow healing are feasible and can be incorporated into routine wound care.

| S-EPMC8982125 | biostudies-literature

Nematostella wound healing

Project description:Transcription profiling by array of wounded Nematostella juvenile polyps compared against uninjured animals and animals exposed to the MAPK inhibitor U0126

2014-03-10 | E-MTAB-2341 | biostudies-arrayexpress

The molecular biology in wound healing & non-healing wound.

Project description:The development of molecular biology and other new biotechnologies helps us to recognize the wound healing and non-healing wound of skin in the past 30 years. This review mainly focuses on the molecular biology of many cytokines (including growth factors) and other molecular factors such as extracellular matrix (ECM) on wound healing. The molecular biology in cell movement such as epidermal cells in wound healing was also discussed. Moreover many common chronic wounds such as pressure ulcers, leg ulcers, diabetic foot wounds, venous stasis ulcers, etc. usually deteriorate into non-healing wounds. Therefore the molecular biology such as advanced glycation end products (AGEs) and other molecular factors in diabetes non-healing wounds were also reviewed.

| S-EPMC5555286 | biostudies-other

End-stage kidney disease: a never healing wound leading to another never healing wound, renal cancer.

Project description:BackgroundEnd-stage kidney disease and acquired cystic kidney disease are the final stages of chronic kidney disease, leading to loss of kidney function and frequent development of tumours. It has been suggested that an inflammatory microenvironment may be responsible for the progressive kidney remodelling and cancer development.MethodsOur aim was to analyse gene expression suggested to be involved in the remodelling of kidneys in end-stage kidney disease, and in the development of preneoplastic lesions and tumours. Immunohistochemistry was employed to assess the cellular localisation of different genes involved in these pathways on representative tissue sections.ResultsCellular (αSMA positive naïve activated fibroblasts, endothelial cells, macrophages) and non-cellular components (cytokines IL6, TGFβ, IL1β, CSF2, fibronectin, laminin, and matrix modifier proteases MMP9 and MMP12) of the inflammatory microenvironment were expressed in the kidneys of patients with end-stage kidney disease. IL6 and FN1 expressing naïve activated fibroblasts and recruited inflammatory cells were the most abundant cellular components of the inflammatory microenvironment.ConclusionThe progressive inflammatory and fibrotic processes in end-stage kidney disease have features recalling those of a never healing wound and may explain the frequent development of kidney cancer.

| S-EPMC10393832 | biostudies-literature

The Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing.

Project description:The timely resolution of wound healing is critical for restoring the skin as a protective barrier. The switch from a proinflammatory to a reparative microenvironment must be tightly regulated. Interleukin (IL)-6 is a key modulator of the inflammatory and reparative process: it is involved in the differentiation, activation, and proliferation of leukocytes, endothelial cells, keratinocytes, and fibroblasts. This review examines the role of IL-6 in the healing of cutaneous wounds, and how dysregulation of IL-6 signaling can lead to either fibrosis or a failure to heal. The role of an IL-6/TGF-? feedback loop is discussed in the context of fibrogenesis, while IL-6 expression and responses in advanced age, diabetes, and obesity is outlined regarding the development of chronic wounds. Current research on therapies that modulate IL-6 is explored. Here, we consider IL-6's diverse impact on cutaneous wound healing.

| S-EPMC7277690 | biostudies-literature

Current Approaches Targeting the Wound Healing Phases to Attenuate Fibrosis and Scarring.

Project description:Cutaneous fibrosis results from suboptimal wound healing following significant tissue injury such as severe burns, trauma, and major surgeries. Pathologic skin fibrosis results in scars that are disfiguring, limit normal movement, and prevent patient recovery and reintegration into society. While various therapeutic strategies have been used to accelerate wound healing and decrease the incidence of scarring, recent studies have targeted the molecular regulators of each phase of wound healing, including the inflammatory, proliferative, and remodeling phases. Here, we reviewed the most recent literature elucidating molecular pathways that can be targeted to reduce fibrosis with a particular focus on post-burn scarring. Current research targeting inflammatory mediators, the epithelial to mesenchymal transition, and regulators of myofibroblast differentiation shows promising results. However, a multimodal approach addressing all three phases of wound healing may provide the best therapeutic outcome.

| S-EPMC7037118 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data